Cyclacel presents phase 1 clinical data showing safety, anti-tumor activity and good oral bioavailability of fadraciclib in patients with advanced solid tumors at the eortc-nci-aacr symposium 2020

A patient with mcl1 amplified endometrial cancer achieved partial response (pr) with 92% target tumor shrinkage on singe agent fadraciclib a patient with mcl1 amplified endometrial cancer achieved partial response (pr) with 92% target tumor shrinkage on singe agent fadraciclib
CYCC Ratings Summary
CYCC Quant Ranking